MedPath

Pilot Study to Determine Efficacy of Cyclamen Europaeum Extract Nasal Spray in Patients With Acute Sinusitis

Not Applicable
Completed
Conditions
ACUTE SINUSITIS
Interventions
Drug: Cyclamen Europaeum
Registration Number
NCT00552773
Lead Sponsor
Dey
Brief Summary

To evaluate the efficacy and safety of Cyclamen europaeum extract 10 % (v/v) compared to placebo in subjects with acute sinusitis

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
48
Inclusion Criteria
  1. Adults age 18-70
  2. Must be symptomatic on the basis of subject assessments of total sympton score.
  3. Evidence of mucopurulence on nasal endoscopy
  4. Evidence of inflammation upon nasal endoscopy
  5. CT scan with radiographic signs of acute sinusitis
  6. Able to complete all study activities or procedures through the end of the study, including all visits and tests, and capable of selfadministration of study medication
  7. Agree to abide by the study protocol and its restrictions
Exclusion Criteria
  1. Known history of hypogammaglobulinemia, immotile cilia syndrome, atrophic rhinitis, rhinitis medicamentosa, or cystic fibrosis
  2. Known hypersensitivity to Cyclamen, Primula, or other Primulaceae
  3. Serious unstable comorbidity such as malignancy (other than squamous or basal cell carcinoma of the skin) or sever renal or hepatic disease.
  4. Abnormal screening laboratory/imaging test results
  5. Condition(s) that compromise the ability to either administer the agent or assess the risks/benefits (eg mucocele, choanal polyp, Stage 4 polyposis or cyst extending below the inferior turbinate, deviated septum, facial trauma, or birth defect)
  6. Expansile mass or bony erosion on sinus radiograph
  7. Females who are pregnant, planning to become pregnant or currently breastfeeding.
  8. History of viral upper respiratory infection (URI) in the past 2 weeks
  9. Temperature greater than 102.5°F
  10. Facial or periorbital edema
  11. Local complications including orbital cellulitis; acute abnormalities of extraocular movements; cavernous vein thrombosis; dental or facial abscess
  12. Altered mental status
  13. Recent nasal or sinus surgery (within 3 months or less) or planned surgery within the next 3 months
  14. Use of intranasal antibiotics within the previous 30 days or systemic antibiotics within the previous 15 days
  15. Use of oral and/or topical nasal decongestants within the previous 7 days
  16. Had radiation therapy or chemotherapy within the previous 12 months
  17. Have used an investigational drug or device within 30 days prior to screening
  18. Have a history of illegal drug or alcohol abuse within the past 5 years
  19. Have major unstable organ system disease that could place the subject at increased risk of complications, interfere with study participation, or confound any of the study objectives Subjects who have asthma, seasonal and/or perennial allergic rhinitis will be allowed to enter the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Cyclamen EuropaeumCyclamen Europaeum-
PlaceboCyclamen Europaeum-
Primary Outcome Measures
NameTimeMethod
Subjective: The mean change in Total Symptom Score (TSS). Objective: The mean change in the percent of sinus occlusion as determined by CT scans.1 year
Secondary Outcome Measures
NameTimeMethod
TSS change from Baseline to each post-dose visit for each symptom scoring Change from Baseline for the individual symptom scores Time to cure rate Frequency of acute sinusitis episodes The presence/absence of mucopurulence and inflamed nasal mucosa1 year

Trial Locations

Locations (25)

Peak Medical Research, LLC

🇺🇸

Owensboro, Kentucky, United States

West Lake Ffamily Practice/Time Point Clinical Research

🇺🇸

Austin, Texas, United States

LAND Clinical Studies, LLC

🇺🇸

West Caldwell, New Jersey, United States

Las Vegas Physicians Research Group

🇺🇸

Henderson, Nevada, United States

Medical Research Associates of Central ew York, PLLC

🇺🇸

North Syracuse, New York, United States

American Institute of Healthcare and Fitness Clinical Research

🇺🇸

Raleigh, North Carolina, United States

ADAC Research, PA

🇺🇸

Greenville, South Carolina, United States

Four Rivers Clinical Research, Inc.

🇺🇸

Paducah, Kentucky, United States

Clinical Health Research LLC

🇺🇸

Sugar Land, Texas, United States

Premier Health Research Center

🇺🇸

Winter Haven, Florida, United States

Clinical Research Connections

🇺🇸

Jonesboro, Arkansas, United States

Alliance Clinical Research

🇺🇸

Birmingham, Alabama, United States

Austin Ear, Nose and Throat Clinic

🇺🇸

Austin, Texas, United States

Southeast Clinical Research

🇺🇸

Gainsville, Florida, United States

Memorial Clinical Research

🇺🇸

Oklahoma City, Oklahoma, United States

San Antonio Ear, Nose & Throat Research

🇺🇸

San Antonio, Texas, United States

Live Oak Allergy and Asthma Clinic

🇺🇸

San Antonio, Texas, United States

Wasatch Clinical Research, LLC

🇺🇸

Salt Lake City, Utah, United States

Center of Research Excellence, LLC

🇺🇸

Oxford, Alabama, United States

Orlando Rangel, MD, PA

🇺🇸

Tampa, Florida, United States

Carolina Research

🇺🇸

Orangeberg, South Carolina, United States

Health Science Research Center

🇺🇸

Cortland, New York, United States

Jones Family Pratice

🇺🇸

Shelby, North Carolina, United States

Greenville Pharmaceutical Research

🇺🇸

Greenville, South Carolina, United States

Virginia Adult and Pediatric Allergy and Asthma, PC

🇺🇸

Richmond, Virginia, United States

© Copyright 2025. All Rights Reserved by MedPath